Watch ANTX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
62
WATCH · insiders 56, shorts 67
Insiders, 90 days
+$10K
net buying · 1 buy, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $224.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$36.2MNET CASH —52W 1.03 – 6.28SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$8.9M | −$8.2M | — | -0.18 | −$7M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$10.6M | −$10M | — | -0.29 | −$12.1M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.3M | −$8.7M | — | -0.28 | −$5.2M | — | — | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$10M | −$9.4M | — | -0.31 | −$6.4M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$7.2M | −$6.5M | — | -0.21 | −$7.6M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$11.5M | −$10.6M | — | -0.35 | −$10.6M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.6M | −$7.5M | — | -0.25 | −$5.3M | — | — | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$14M | −$12.7M | — | -0.43 | −$12M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$15.9M | −$14.4M | — | -0.48 | −$14.4M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$18.3M | −$16.6M | — | -0.56 | −$17.6M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.8M | −$16.9M | — | -0.52 | −$17.1M | — | — | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$18.2M | −$16.7M | — | -0.65 | −$11.8M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$38.1M | −$35.2M | — | -1.16 | −$29.8M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$56.8M | −$51.3M | — | -1.72 | −$49.3M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$69.6M | −$64.7M | — | -2.74 | −$53.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$42.3M | −$41M | — | -2.79 | −$33.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$21.6M | −$21.5M | — | -10.64 | −$20.5M | — | — | — | — |
Every number comes from AN2 Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.